AGTC Applied Genetic Technologies Corporation

3.93
+0.07  (2%)
Previous Close 3.85
Open 3.90
Price To book 0.62
Market Cap 70994556
Shares 18,087,785
Volume 101,103
Short Ratio 0.95
Av. Daily Volume 177,828

SEC filingsSee all SEC filings

  1. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 171083355
  2. 8-K - Current report 171082218
  3. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 171076704
  4. 8-K - Current report 171039179
  5. 8-K - Current report 17999968

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 continues to enroll - September 2017.
AAV Gene Therapy
CNGB3 Achromatopsia
Phase 1/2 completion of enrollment due 1Q 2018 with data due after the last patient has been followed for six months (est 3Q 2018).
rAAV-hRS1
X-linked retinoschisis (XLRS)

Latest News

  1. ETFs with exposure to Applied Genetic Technologies Corp. : October 16, 2017
  2. AGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated Achromatopsia
  3. Earnings Review and Free Research Report: Applied Genetic Announced Q4 and Full Year FY17 Results
  4. AGTC to Present at Upcoming Gene Therapy Conferences
  5. Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q4, 2017 By the Numbers : September 25, 2017
  6. Earnings Review and Free Research Report: Aviragen Reported its Q4 and Full Year FY17 Results
  7. AGTC to Present at Upcoming Conferences
  8. ETFs with exposure to Applied Genetic Technologies Corp. : September 19, 2017
  9. Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: 2017 By the Numbers : September 18, 2017
  10. Edited Transcript of AGTC earnings conference call or presentation 13-Sep-17 12:00pm GMT
  11. Applied Genetic Technologies posts 4Q loss
  12. AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017
  13. AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer
  14. AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 13, 2017
  15. AGTC and the Foundation Fighting Blindness Announce Partnership Agreement
  16. AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene
  17. AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
  18. Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
  19. AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa